Ares Financial Consulting
MIRM icon

Ares Financial Consulting’s Mirum Pharmaceuticals MIRM Stock Holding History

Ares Financial Consulting’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-27
Closed -$3.16K – 1109
2026
Q2 		$3.16K Buy
+27
New +$2.71K ﹤0.01% 813

Other funds holding MIRM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Ares Financial Consulting's MIRM Position: Q3 2026 in Review

Ares Financial Consulting sold out of Mirum Pharmaceuticals (MIRM) in Q3 2026, closing a stake of 27 shares — an estimated $3.16K sold.

Ares Financial Consulting first reported a position in MIRM in Q2 2026 and held it in 1 quarter. The position peaked at $3.16K in Q2 2026. 182 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Ares Financial Consulting reported no remaining Mirum Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 27 Mirum Pharmaceuticals shares in Q3 2026, an estimated $3.16K.
  • Ares Financial Consulting first reported a position in Mirum Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Mirum Pharmaceuticals position peaked at $3.16K in Q2 2026.
  • 182 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.